308 560

Cited 0 times in

Cited 0 times in

Development of a metabolite calculator for diagnosis of pancreatic cancer

DC Field Value Language
dc.contributor.authorChoi, Munseok-
dc.contributor.authorPark, Minsu-
dc.contributor.authorLee, Sung Hwan-
dc.contributor.authorLee, Min Jung-
dc.contributor.authorPaik, Young-Ki-
dc.contributor.authorJang, Sung Il-
dc.contributor.authorLee, Dong Ki-
dc.contributor.authorLee, Sang-Guk-
dc.contributor.authorKang, Chang Moo-
dc.date.accessioned2023-07-12T03:15:57Z-
dc.date.available2023-07-12T03:15:57Z-
dc.date.created2023-07-28-
dc.date.issued2023-06-
dc.identifier.issn2045-7634-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/195555-
dc.description.abstractBackground: Carbohydrate antigen (CA) 19–9 is a known pancreatic cancer (PC) biomarker, but is not commonly used for general screening due to its low sensitivity and specificity. This study aimed to develop a serum metabolites-based diagnostic calculator for detecting PC with high accuracy. Methods: A targeted quantitative approach of direct flow injection-tandem mass spectrometry combined with liquid chromatography–tandem mass spectrometry was employed for metabolomic analysis of serum samples using an Absolute IDQ™ p180 kit. Integrated metabolomic analysis was performed on 241 pooled or individual serum samples collected from healthy donors and patients from nine disease groups, including chronic pancreatitis, PC, other cancers, and benign diseases. Orthogonal partial least squares discriminant analysis (OPLS-DA) based on characteristics of 116 serum metabolites distinguished patients with PC from those with other diseases. Sparse partial least squares discriminant analysis (SPLS-DA) was also performed, incorporating simultaneous dimension reduction and variable selection. Predictive performance between discrimination models was compared using a 2-by-2 contingency table of predicted probabilities obtained from the models and actual diagnoses. Results: Predictive values obtained through OPLS-DA for accuracy, sensitivity, specificity, balanced accuracy, and area under the receiver operating characteristic curve (AUC) were 0.9825, 0.9916, 0.9870, 0.9866, and 0.9870, respectively. The number of metabolite candidates was narrowed to 76 for SPLS-DA. The SPLS-DA-obtained predictive values for accuracy, sensitivity, specificity, balanced accuracy, and AUC were 0.9773, 0.9649, 0.9832, 0.9741, and 0.9741, respectively. Conclusions: We successfully developed a 76 metabolome-based diagnostic panel for detecting PC that demonstrated high diagnostic performance in differentiating PC from other diseases. © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherJohn Wiley & Sons Ltd.-
dc.relation.isPartOfCancer Medicine-
dc.relation.isPartOfCANCER MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleDevelopment of a metabolite calculator for diagnosis of pancreatic cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorChoi, Munseok-
dc.contributor.googleauthorPark, Minsu-
dc.contributor.googleauthorLee, Sung Hwan-
dc.contributor.googleauthorLee, Min Jung-
dc.contributor.googleauthorPaik, Young-Ki-
dc.contributor.googleauthorJang, Sung Il-
dc.contributor.googleauthorLee, Dong Ki-
dc.contributor.googleauthorLee, Sang-Guk-
dc.contributor.googleauthorKang, Chang Moo-
dc.identifier.doi10.1002/cam4.6233-
dc.relation.journalcodeJ00449-
dc.identifier.eissn2045-7634-
dc.identifier.pmid37350558-
dc.subject.keywordbiomarker-
dc.subject.keywordcalculator-
dc.subject.keyworddiagnosis-
dc.subject.keywordmetabolomics-
dc.subject.keywordpancreatic cancer-
dc.contributor.alternativeNameKang, Chang Moo-
dc.contributor.affiliatedAuthorChoi, Munseok-
dc.contributor.affiliatedAuthorJang, Sung Il-
dc.contributor.affiliatedAuthorLee, Dong Ki-
dc.contributor.affiliatedAuthorLee, Sang-Guk-
dc.contributor.affiliatedAuthorKang, Chang Moo-
dc.identifier.scopusid2-s2.0-85162916350-
dc.identifier.wosid001019826600001-
dc.citation.volume12-
dc.citation.number15-
dc.citation.startPage15933-
dc.citation.endPage15944-
dc.identifier.bibliographicCitationCancer Medicine, Vol.12(15) : 15933-15944, 2023-06-
dc.identifier.rimsid80406-
dc.type.rimsART-
dc.description.journalClass1-
dc.description.journalClass1-
dc.subject.keywordAuthorbiomarker-
dc.subject.keywordAuthorcalculator-
dc.subject.keywordAuthordiagnosis-
dc.subject.keywordAuthormetabolomics-
dc.subject.keywordAuthorpancreatic cancer-
dc.subject.keywordPlusDUCTAL ADENOCARCINOMA-
dc.subject.keywordPlusSERUM-
dc.subject.keywordPlusRESECTION-
dc.subject.keywordPlusSURVIVAL-
dc.subject.keywordPlusIDENTIFICATION-
dc.subject.keywordPlusBIOMARKERS-
dc.type.docTypeArticle; Early Access-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalWebOfScienceCategoryOncology-
dc.relation.journalResearchAreaOncology-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.